


DAFTAR PUSTAKA

1. Hostalek U. Global epidemiology of prediabetes-present and future perspectives. *Clinical Diabetes and Endocrinology*. 2019; 5(5):1-5.
2. International Diabetes Federation. *IDF Diabetes Atlas*. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015
3. National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation. Prevalence of prediabetes. [Internet]. CDC. 2022.[cited 30 September 2022]. Available from <https://www.cdc.gov/diabetes/data/statistics-report/prevalence-of-prediabetes.html>
4. Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G. Prevalence of Prediabetes Among Adolescents and Young Adults in the United States, 2005-2016. *JAMA Pediatr*. 2020. 1;174(2): e194498
5. Echouffo-Tcheugui JB, Selvin E. Prediabetes and What It Means: The Epidemiological Evidence. *Annu Rev Public Health*. 2021;42: 59-77
6. Kementerian Kesehatan. *Riset Kesehatan Dasar*. Jakarta. 2018
7. Lemme, B.H. *Development in Adulthood*. Boston.1995
8. World Health Organization (WHO). Adolescent and young adult health. [Internet]. WHO. 2021 [cited 30 September 2022] available from www.who.int/news-room/factsheets/detail/adolescents-health-risks-and-solutions
9. Kementerian Kesehatan. *Klasifikasi umur menurut kategori*. Jakarta. 2019

10. Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021; 24;326(8):736-43
11. C.B. Weir, A. Jan. BMI classification percentile and cut off points. StatPearls, StatPearls Publishing, Treasure Island (FL). StatPearls Publishing LLC.2020
12. Baik I. Optimal cutoff points of waist circumference for the criteria of abdominal obesity: comparison with the criteria of the International Diabetes Federation. *Circ J*. 2009;73(11):2068-75
13. Kementerian Kesehatan. Survei Kesehatan Indonesia. Jakarta. 2023
14. Purnell JQ. Definitions, Classification, and Epidemiology of Obesity. *Endotext*. 2023
15. O'Connell JM, Manson SM. Understanding the Economic Costs of Diabetes and Prediabetes and What We May Learn About Reducing the Health and Economic Burden of These Conditions. *Diabetes Care*. 2019 ;42(9):1609-11
16. Dall TM, Yang W, Halder P. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. *Diabetes Care*. 2014; 37: 3172– 9
17. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. *Diabetes Care* 2018; 41: 917–28
18. American Diabetes Association. Chapter 5. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes - 2018. *Diabetes Care*. 2018;41(Supplement 1):S51- S54.
19. Sequiera IR, Poppitt SD. HbA1c as a marker of prediabetes: a reliable screening tool or not?. *Insight Nutr Metabol*. 2017; 1: 21-9

20. Dorcely B, Katz K, Jagannathan R, Chiang S, Oluwadare B, Goldberg I. Novel biomarkers for prediabetes, diabetes, and associated complications. *Diabetes, Metabolic syndrome and Obesity: Targets and Therapy*; 2017;10: 345-61
21. Sumner AE, Duong MT, Brianna A, Paola C, Ricks M, Mabundo LS. Glycated albumin identifies prediabetes not detected by HbA1c: The African In America Study. *Clinical Chemistry*. 2016; 62 (11); 1524-32
22. Bala M, Meenakshi, Aggarwal S. Assessment of fructosamine levels and its utility in patients of prediabetes. *International J. of Healthcare and Biomedical Research*. 2020; 08-03; 5-10
23. Kaur S, Mahajan M. Fetuin A: A Newer Marker for Pre Diabetes. *Journal of Advances in Medicine and Medical Research*, 2016.17(1), 1-7
24. Chan CL, Pyle L, Kelsey M, Newnes L, Zeitler PS, Nadeau KJ. Screening for type diabetes and prediabetes in obese youth; evaluate alternate markers of glycemia—1,5 anhydroglucitol, fructosamin and glycated albumin. *Pediatr Diabetes*. 2016; 17(3); 206-11
25. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemetic marker. *Diabetes Technol Ther*. 2003;5(3):355-63
26. Selvin E, Rawlings AM, Grams M, Klein R, Steffes M, Coresh J. Association of 1,5 Anhydroglucitol with diabetes an microvascular conditions. *NIH Access*. 2014; 60 (11): 1409-18
27. Pramodkumar TA, Jayashri R, Gokulakhrisnan K, Velmurugan K, Pradepa R, Mohan R. Relationship of glycemetic control markers – 1,5 anhydroglucitol,



- frutosamin and glycated hemoglobin. *Indian J Endocrinol Metab.* 2016; 20(5):690-95
28. Public Health England (2014) Adult obesity and type 2 diabetes. PHE, London. 2014. [cited 31 July 2014] Available from: <https://bit.ly/2p8SHqj>
29. Marmot M, McKenna C. The health of nations. *BJPsych Bull.* 2023;47(1):56-9.
30. Centers for Disease Control and Prevention. National Diabetes Statistics Report [Internet]. CDC. 2022. [cited 29 June 2022]. Available from <https://www.cdc.gov/diabetes/data/statistics-report/index.html>.
31. Blum J, Aeschbacher S, Schoen T, Bossard M, Pumpol K, Blasier N et al. Prevalence of prediabetes according to HbA1c versus fasting plasma glucose criteria in healthy adults. *Acta Diabetol.* 2015 ;52: 631-2
32. Stefanaki, C. "Prediabetes and Adolescence—Trends, Causes, Effects, and Screening." *US endocrinology* . 2016;12(2): 94-8
33. Kacker, Sudhanshu, Saboo N, Jitender. "Prediabetes: Pathogenesis and Adverse Outcomes." .2018: 4(2): 1-6
34. Perkeni. *Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*. Jakarta. 2021.
35. Kitchlew R, Chachar AZ, Haider M, Saleem AR, Mirza MS, Latif S et al. Pre-diabetes; prevalence of pre-diabetes in our local population. *Professional Medical Journal.* 2017; 1; 24(12).
36. Rongies, Wolska M, Strzalka-Goc K, Slomka B, Krasnodebski P. The Prevalence of Prediabetes in Healthcare Professionals assessed based on Glycated Hemoglobin Levels. *J Diabetes Metab.*2016. 7:660

37. Lim CT, Kola B, Feltrin D, Perez-Tilve D, Tschöp MH, Grossman AB, et al. Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism. *Mol Cell Endocrinol.* 2013;365(2):303-8
38. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. *Physiol Rev.* 2018;98(4):2133-223
39. Yazıcı D, Sezer H. Insulin Resistance, Obesity and Lipotoxicity. *Adv Exp Med Biol.* 2017; 960: 277-304
40. Dagogo-Jack S, Edeoga C, Ebenibo S, Nyenwe E, Wan J. Lack of racial disparity in incident prediabetes and glycemic progression among black and white offspring of parents with type 2 diabetes: the pathobiology of prediabetes in a biracial cohort (POP-ABC) study. *J Clin Endocrinol Metab* 2014;99:E1078–87
41. Bilous R, Donnelly R. Handbook of Diabetes, 4th Edition: Normal Physiology of Insulin Secretion and Action. 2010
42. American Diabetes Association; Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers. *Clin Diabetes.* 2022; 40 (1): 10–38.
43. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J.* 2020;41(2):255-323
44. Nam HK, Cho WK, Kim JH, Rhie YJ, Chung S, Lee KH, Suh BK. HbA1c Cutoff for Prediabetes and Diabetes Based on Oral Glucose Tolerance Test in Obese Children and Adolescents. *J Korean Med Sci.* 2018; 19;33(12)e93

45. Katulanda GW, Katulanda P, Dematapitiya C, Dissanayake HA, Wijeratne S, Sheriff MHR, et al. Plasma glucose in screening for diabetes and pre-diabetes: how much is too much? Analysis of fasting plasma glucose and oral glucose tolerance test in Sri Lanka. *BMC Endocr Disord.* 2019;22;19(1):11.
46. Aekplakorn W, Tantayotai V, Numsangkul S. Detecting Pre diabetes and Diabetes: Agreement between Fasting Plasma Glucose and Oral Glucose Tolerance Test in Thai Adults. *J Diabetes Res.* 2015: 396505.
47. Koga M. 1,5-Anhydroglucitol and glycated albumin in glycemia. *Adv Clin Chem.* 2014;64:269-301.
48. Yoo HY, Kwak BO, Son JS, Kim KS, Chung S. Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes. *Ann Pediatr Endocrinol Metab.* 2015;20(4):192-7.
49. E.M. Wright, Renal Na(p)-glucose cotransporters, *Am. J. Physiol. Renal Physiol.* 2001; 280 (1) F10–F18
50. M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, Habitual intake of daily products influences serum 1,5-anhydroglucitol levels independently of plasma glucose, *Diabetes Res. Clin. Pract.* 2010; 90 (1) 122–25
51. Paroni R, Ceriotti F, Galanello R, Battista L, Panico A, Scurati E et al. Performance characteristic and clinical utility of an enzymatic methods. *Cin Biochem.* 2007. 40 (18): 1398-405
52. Li S, Heng X, Sheng H, Wang Y, Yu C. Determination of glycemic monitoring marker 1,5-anhydroglucitol in plasma by liquid chromatography-electrospray tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2008;875(2):459-64.

53. Halama A, Kulinski M, Kader SA, Satheesh NJ, Samra AB, Suhre K, et al. Measurement of 1,5-Anhydroglucitol in blood and saliva: from nontargeted metabolomic to biochemical assay. *Journal of Translational Medicine*. 2016 ; 140: 1-9
54. Dungan KM. 1,5-anhydroglucitol as a marker of short-term glyceimic control and glyceimic excursions. *Expert Rev Mol Diagn*. 2008 ;8(1):9-19.
55. Seok H, Huh JH, Kim HM, Lee BW, Kang ES, Lee HC et al. 1,5-anhydroglucitol as a useful marker for assessing short-term glyceimic excursions in type 1 diabetes. *Diabetes Metab J*. 2015;39(2):164-70.
56. Malkan UY, Gunes G, Corakci A. Rational diagnose of diabetes the comparison of 1,5-Anhydroglucytrol with other glyceimic markes. *Springer plus*. 2015;4;57-9
57. Kim WJ, Park CY. 1,5Anhydroglucitol in diabetes mellitus. *Endocrine*. 2013;43(1):33-40.
58. Stettler C, Stahl M, Allemann S, Diem P, Schmidlin K, Zwahlen M, et al Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. *DiabetesCare*. 2008;31(8):1534-5
59. Juraschek SP, Miller ER 3rd, Appel LJ, Christenson RH, Sacks FM, Selvin E. Effects of dietary carbohydrate on 1,5-anhydroglucitol in a population without diabetes: results from the OmniCarb trial. *Diabet Med*. 2017;34(10):1407-13.
60. Su H, Ma X, Yin J. Serum 1,5 Anhydroglucitol levels slightly increase rather than decrease after glucose load subjects with difference glucose tolerance status. *Acta Diabetaco*. 2017; 54; 463-70

61. Pramodkumar TA, Jayashri R, Gokulakrishnan K, Velmurugan K, Pradeepa R, Anjana RM, *et al.* Relationship of glycemc control markers - 1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance. *Indian J Endocr Metab* 2016;20:690-5.
62. Kim MJ, Jung HS, Hwang-Bo Y. Evaluation of 1,5-anhydroglucitol as a marker for glycemc variability in patients with type 2 diabetes mellitus. *Acta Diabetol.* 2013; 50(4):505–510
63. Goto M, Yamamoto-Honda R, Shimbo T. Correlation between baseline serum 1,5-anhydroglucitol levels and 2-h post-challenge glucose levels during oral glucose tolerance tests. *Endocr J.* 2011; 58(1):13–17
64. Ikeda N, Hara H, Hiroi Y. Ability of 1,5-anhydro-D-glucitol values to predict coronary artery disease in a non-diabetic population. *Int Heart J.* 2015; 56(6):587–91
65. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. *JAMA.*2016;315(21):2284–91
66. Peltzer K, Pengpid S, Samuels TA, Özcan NK, Mantilla C, Rahamefy OH, *et al.* Prevalence of overweight/obesity and its associated factors among university students from 22 countries. *Int J Environ Res Public Health.* 2014;11(7):7425-41
67. Muscogiuri G, Verde L, Vetrani C, Barrea L, Savastano S, Colao A. Obesity: a gender-view. *J Endocrinol Invest.* 2024; 47(2):299-306.

68. Tramunt B, Smati S, Grandgeorge N, Lenfant F, Arnal JF, Montagner A, et al. Sex differences in metabolic regulation and diabetes susceptibility. *Diabetologia*. 2020; 63(3):453–61
69. Decroli, E., Aprilia, D., Kam, A., Rahmadi, A. Body mass index and total testosterone level in obese male pre-diabetic patients: correlation with homeostasis model assessment of insulin resistance. *Bali Medical Journal*. 2024; 13(1): 427-30.
70. Guthold, R.; Stevens, G. A.; Riley, L. M.; Bull, F.C. Global trends in insufficient physical activity among adolescents: A pooled analysis of 298 population-based surveys with 1.6 million participants. *Lancet Child. Adolesc. Health*. 2020; 4, 23–35
71. D'Adamo E, Caprio S. Type 2 diabetes in youth: epidemiology and pathophysiology. *Diabetes Care*. 2011;34 Suppl 2(Suppl 2):S161-5
72. Weiss R, Dufour S, Taksali SE, Tamborlane WV, Petersen KF, Bonadonna RC, et al. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. *Lancet*. 2003;362(9388):951-7
73. Bacong AM, Gibbs SL, Rosales AG, Frankland TB, Li J, Daida YG, et al. Obesity Disparities Among Adult Single-Race and Multiracial Asian and Pacific Islander Populations. *JAMA Netw Open*. 2024;4;7(3)
74. Jeong SM, Lee DH, Rezende LFM, Giovannucci EL. Different correlation of body mass index with body fatness and obesity-related biomarkers according to age, sex and race-ethnicity. *Sci Rep*. 2023;13(1):3472

75. Haam JH, Kim BT, Kim EM, Kwon H, Kang JH, Park JH, et al. Diagnosis of Obesity: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity. *J Obes Metab Syndr*. 2023;32(2):121-9
76. Zhen J, Shuyun L, Guoru Z, Hao P, Nithushi R S, Aimin X, et al. Association of waist circumference with hemoglobin A1c and its optimal cutoff for identifying prediabetes and diabetes risk in the Chinese population. *Internal and Emergency Medicine*. 2022; 17: 2039 - 44.
77. Al-Sharafi BA, Qais AA, Salem K, Bashaib MO. Family History, Consanguinity and Other Risk Factors Affecting the Prevalence of Prediabetes and Undiagnosed Diabetes Mellitus in Overweight and Obese Yemeni Adults. *Diabetes Metab Syndr Obes*. 2021;14:4853-63
78. Ramezankhani A, Habibi-Moeini AS, Zadeh SST, Azizi F, Hadaegh F. Effect of family history of diabetes and obesity status on lifetime risk of type 2 diabetes in the Iranian population. *J Glob Health*. 2022;12:04068.
79. Hsu WH, Tseng CW, Huang YT, Liang CC, Lee MY, Chen SC. Common Risk Factors in Relatives and Spouses of Patients with Type 2 Diabetes in Developing Prediabetes. *Healthcare (Basel)*. 2021;9(8):1010
80. Van't Riet E, Dekker, J. M., Sun Q, Nijpels G, Hu F. B, van Dam R.M. Role of adiposity and lifestyle in the relationship between family history of diabetes and 20-year incidence of type 2 diabetes in U.S. women. *Diabetes Care*. 2010; 33, 763–67.
81. Chen C. M, Yeh M.C. The prevalence and determinants of impaired fasting glucose in the population of Taiwan. *BMC Public Health*. 2013; 13,1123.

82. Kusuma I, Syarif S. Predictors of prediabetes and undiagnosed diabetes mellitus based on HbA1c levels in Indonesia. *Jurnal Ilmu Kesmas*. 2023; 14(2): 185-97
83. Park KS, Hwang SY. Lifestyle-related predictors affecting prediabetes and diabetes in 20-30-year-old young Korean adults. *Epidemiol Health*. 2020;42:e2020014
84. Sosibo AM, Mzimela NC, Ngubane PS, Khathi A. Prevalence of pre-diabetes in adults aged 25 - 45 years in a Durban-based clinical setting, South Africa: A retrospective study. *Primary Care Diabetes*. 2023(6):650-4.
85. Ohigashi M, Osugi K, Kusunoki Y, Washio K, Matsutani S, Tsunoda T, et al. Association of time in range with hemoglobin A1c, glycated albumin and 1,5 anhydro-d-glucitol. *J Diabetes Investig*. 2021;12(6):940-49.
86. Amseer H S, Saleh B O, Salman E N. The Role of serum of 1, 5-anhydroglucitol, Leptin and Glycated Albumin in Prediction of Pre-Diabetes Mellitus Type2 in Overweight-obese and normal weigh healthy subjects. *Acta Biomed*. 2023;94(2):e2023083.
87. Sastroasmoro S, Ismael S. *Dasar-dasar metodologi penelitian klinis*. Edisi ke-4. Jakarta: Sagung Seto. 2011
88. Hardisman. *Penelitian diagnostik dan prognostik*. Jakarta: Prenadamedia Group. 2021
89. Xu H, Pan J, Chen Q. The progress of clinical research on the detection of 1,5-anhydroglucitol in diabetes and its complications. *Front Endocrinol*. 2024;15:1383483
90. Jiménez-Sánchez C, Mezza T, Sinturel F, Li L, Di Giuseppe G, Quero G et al. Circulating 1,5-anhydroglucitol as a biomarker of β -cell mass independent of a

diabetes phenotype in human subjects. *J Clin Endocrinol Metab.* 2022;107:2833–43.

91. Shen Y, Si Y, Lu J, Ma X, Zhang L, Mo Y, et al. Association between 1,5- anhydroglucitol and acute C peptide response to arginine among patients with type 2 diabetes. *J Diabetes Res.* 2020; 21:4243053

